Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Attends SCC 2018

[2018-06-27] 

Guangzhou, China – From April 5 to April 8, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") attended the 20th South China International Congress of Cardiology ("SCC 2018") and hosted a case competition. Themed on "Science, Cooperation, Innovation", the SCC 2018 invited domestic and overseas cardiologists to exchange ideas on the new achievement in the treatment and prevention of cardiovascular diseases as well as to have discussion on the hot topics of the cardiovascular field to enhance their theoretical knowledge and surgical skill, so as to promote the development of China's cardiology field.
 
In this conference, MicroPort® hosted three case competitions involving 18 cases in total. MicroPort® invited 15 renowned experts to serve as moderators, including Professor Jianping Li of Peking University First Hospital, Professor Qiangsun Zheng of the Second Affiliated Hospital of Xi'an Jiaotong University, Professor Leisheng Ru of Peace Hospital, Professor Liangqiu Tang of Yuebei People's Hospital, and Professor Qiang Xie of the First Affiliated Hospital of Xiamen University. In the end, the case of Primary PCI treatment of CTO by Professor Guoxiang Shi of the First Affiliated Hospital of Nanchang University, the case of open LAD CTO through lateral branch of outer membrane by guide wire kissing technique by Professor Minggang Zhou of the Third People's Hospital of Chengdu, and the case of retrograde CTO by Professor Haipeng Wang of the First Affiliated Hospital of Soochow University respectively won the first place in the three case competitions. Since 2016, MicroPort® hosted the case competition in various national-level congresses and has received positive feedback. It was the third time for MicroPort® to host such seminar in the CCIF, which fully demonstrated the excellent performance of its stents. Meanwhile, this case competition was live broadcasted via Dr. King studio and MicroPort® online platform, which attracted more than 1,500 audience to watch online. It provided opportunities for physicians in rural areas to learn more advanced technologies.
 
During the conference, MicroPort® and MicroPort® EP set up a booth to display several innovative products such as Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") and Columbus™ 3D EP Navigation System ("Columbus™"), attracting many attendees to pay a visit and inquire for product information. After trying out Columbus™ and its matching catheter FireMagic™, some experts in attendance showed high recognition in their stability and reliability. Meanwhile, MicroPort® carried out satisfaction survey activities during the conference. Experts spoke highly of MicroPort®'s cardiovascular products such as Firehawk® and Firebird2® and offered suggestions regarding the product R&D.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2018 MicroPort Scientific Corporation

CONTACT:
Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953
Email: ir@microport.com

 

[Prev]:MicroPort® Endovascular Attends Lijiang Vascular Surgery Intervention Treatment Summit
[Next]:MicroPort® CRM Announces PMDA Approval in Japan of PLATINIUM™ 4LV SonR®CRT-D
PLATINIUM™ 4LV SonR* combines quadripolar IS-4 left ventricular pacing options with SonR, the world's first and only sensor-based therapeutic optimization, for cardiac resynchronization therapy.